Share FDA Approves Genentech's WILSERDLY (Giredestrant), a Next-Generation Oral SERD, for ER-Positive, ESR1-Mutated Advanced Breast Cancer

Business Wire · RHHBF · November 16, 2026

FDA Approves Genentech's WILSERDLY (Giredestrant), a Next-Generation Oral SERD, for ER-Positive, ESR1-Mutated Advanced Breast Cancer

Stocks To Buy Now app

Get the app for more

Explore stock news, insights and company research.

Get the app →
Source: Business Wire ↗